← All trials
NCT05611931
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2022
- Primary completion
- Jun 30, 2024
- Completion date
- Aug 31, 2025
- First posted
- Nov 10, 2022
- Last posted
- Nov 18, 2022
- Enrollment
- 220
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Karyopharm Therapeutics IncLead sponsor
- Australia New Zealand Gynaecological Oncology GroupCollaborator
- Belgium and Luxembourg Gynaecological Oncology GroupCollaborator
- European Network for Gynaecological Oncological TrialCollaborator
- GOG Foundation, Inc.Collaborator
- North Eastern Germany Society of Gynaecologic OncologyCollaborator
- Central and Eastern European Oncology GroupCollaborator
- Katholieke Universiteit LeuvenCollaborator
- Multicenter Italian Trials in Ovarian CancerCollaborator
- Grupo Español de Investigación en Cáncer de OvarioCollaborator
- Mario Negri InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.